Skip to Content
Shadow

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Agile Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
Twirla Experienced Another Quarter of Double-Digit Demand Growth in First Quarter 2022 Twirla Business Plan Progressing Company Anticipates Future 2022 Quarterly Operating Expenses to be Lower Management to Host Conference Call Today, Thursday, May 12, 2022 at 4:30 p.m....
Toggle Summary Agile Therapeutics Announces Findings of First-Year Post-Marketing Pharmacovigilance in ACOG Poster Presentation
PRINCETON, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today publicly released the findings of its first year of post-marketing pharmacovigilance safety surveillance for Twirla ® (levonorgestrel and ethinyl estradiol) transdermal...
Toggle Summary Agile Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on Thursday, May 12, 2022
Live Conference Call and Webcast at 4:30 p.m. ET PRINCETON, N.J., May 03, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report first quarter 2022 financial results after the market close on Thursday, May 12, 2022....
Toggle Summary Agile Therapeutics Announces 1-For-40 Reverse Stock Split
PRINCETON, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile”), a women's healthcare company, today announced that the Board approved a 1-for-40 reverse stock split, to be effective 5:00 p.m. on Tuesday, April 26, 2022....
Toggle Summary Agile Therapeutics Announces First Quarter 2022 Prescription Data for Twirla®
29% increase in Twirla cycles 27% increase in total prescriptions (TRx) of Twirla PRINCETON, N.J., April 14, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced Twirla prescription data for the first quarter 2022....
Toggle Summary Agile Therapeutics Receives $4.7M After Selling Net Operating Loss Tax Benefits Through New Jersey Economic Development Program
PRINCETON, N.J., April 11, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced the receipt of $4.7 million in net proceeds from the sale of tax benefits pursuant to the Company’s participation in the New Jersey Economic Development...
Toggle Summary Agile Therapeutics® Announces Poster Presentation at the 2022 Annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecologists (ACOG)
The abstract was accepted by ACOG and will be presented from May 4th – May 6th, 2022 PRINCETON, N.J., April 07, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that data from the company’s first-year of postmarketing pharmacovigilance...
Toggle Summary Agile Therapeutics® Partners with Award-Winning Director Maya Albanese on First Twirla® Commercial, Targeting Gen Z
Partners with Award-Winning Director Maya Albanese “Patch and Play” introduces the features of the Twirla (levonorgestrel and ethinyl estradiol) transdermal system, while highlighting the power of female friendships PRINCETON, N.J., March 31, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc....
Toggle Summary Agile Therapeutics Reports Fourth Quarter & Full Year 2021 Financial Results and Provides Corporate Update
Twirla Demand Grows with Cycles Dispensed and Total Prescriptions (TRx) Up 35% and 33% Respectively in Fourth Quarter 2021 vs Third Quarter 2021 New Twirla Connected TV Commercial Expected to launch in April 2022 and Contribute to Further Demand Growth Company Advances Business Plan Designed to...
Toggle Summary Agile Therapeutics Announces Closing of $4.85 Million Registered Direct Offering
PRINCETON, N.J., March 14, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) ("Agile Therapeutics" or the "Company"), a women's healthcare company, today announced that it has closed its previously announced registered direct offering with a single healthcare-focused institutional...
Shadow